๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials China
Clinical trial register · China

Studies with a Chinese investigative site

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 451 Beijing 25 Shenzhen 23 Zhongshan 17 Nanning 17
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou451 Beijing25 Shenzhen23 Zhongshan17 Nanning17
All 55 locations
Target enrolment
to

Trials in this register

490 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer
NCT06764680Colorectal Cancer Metastatic, Chemotherapy, Targeted Therapy, Immunotherapy
Sun Yat-sen University
Phase 2
57
Guangzhou
2024-12-31
Recruiting
An Exploratory Study on the Failure of Immunotherapy With Voronib Combined With Everolimus
NCT06730672Renal Cell Carcinoma Stage I
Sun Yat-sen University
Phase 2
80
Guangzhou, Zhengzhou
2024-12-30
Recruiting
Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma
NCT06446154Hepatocellular Carcinoma, Immune Checkpoint Inhibitors, Anti-angiogenic Therapy, Second-line Treatment
Sun Yat-sen University
Phase 2
36
Guangzhou
2024-12-27
Recruiting
The Optimal Radioimmunotherapy Combinations for Advanced TNBC
NCT06735131Triple-Negative Breast Cancer (TNBC)
Sun Yat-sen University
Phase 2
60
Guangzhou
2024-12-20
Recruiting
TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma
NCT06740370Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization, Anti-PD1 Antibody, Lenvatinib
Sun Yat-sen University
Not applicable
32
Beijing
2024-12-13
Recruiting
Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Centrally Located Early-stage Non-small Cell Lung Cancer
NCT06730295Lung Cancer (NSCLC)
Sun Yat-sen University
Phase 2
52
Guangzhou
2024-12-10
Recruiting
Clinical Study on the Safety, Efficacy and Pharmacokinetics of Telpegfilgrastim in Pediatric Cancer Patients with Chemotherapy
NCT06857292Chemotherapy-Induced Neutropenia
Sun Yat-sen University
Phase 2
97
Guangzhou
2024-12-01
Recruiting
ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC
NCT06426511Lung Cancer, Nonsmall Cell
Sun Yat-sen University
Phase 2
80
Guangzhou
2024-12-01
Recruiting
Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
NCT06734702Neoadjuvant Therapy, Concurrent Chemoradiotherapy, Immunotherapy, Locally Advanced Non-Small Cell Lung Cancer
Sun Yat-sen University
Phase 3
497
Guangzhou
2024-11-30
Recruiting
Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer
NCT06719700Toripalimab, Surufatinib, Chemoradiotherapy, Limited-stage Small Cell Lung Cancer (LS-SCLC)
Sun Yat-sen University
Phase 2
47
Guangzhou
2024-11-30
Recruiting
Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT06669611Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 3
242
Guangzhou
2024-11-27
Not yet open
Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment
NCT06662877Biliary Tract Cancer, Second Line Treatment, Chemotherapy, Tyrosine Kinase Inhibitor
Sun Yat-sen University
Phase 2/3
206
Guangzhou
2024-11-25
Recruiting
Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma
NCT06730308Thymoma
Sun Yat-sen University
Phase 2
45
Guanzhou
2024-11-20
Recruiting
WHO Mental Health Gap Action Program (mhGAP) for Improving Child Mental and Behavioral Disorder Service Quality in China
NCT06702410Neurodevelopmental Disorders
Sun Yat-sen University
Not applicable
375
Zhongshan
2024-11-20
Recruiting
Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma
NCT07602049Soft Tissue Sarcoma (STS), Osteosarcoma
Sun Yat-sen University
Phase 2
57
Guangzhou
2024-11-20
Recruiting
A Deep Learning Model for Diagnosing Lymph Node Metastasis in Nasopharyngeal Carcinoma(NPC)
NCT06829147Nasopharyngeal Cancinoma (NPC), Lymph Node Metastasis
Sun Yat-sen University
Observational
500
Guangzhou
2024-11-19
Recruiting
Inhaling Penehyclidine to Prevent Perioperative Respiratory Adverse Events in Children at Risk Undergoing Sevoflurane Anesthesia
NCT06624696Respiratory Hypersensitivity, Perioperative Respiratory Adverse Events, Anticholinergics, Inhalation Therapy; Complications
Sun Yat-sen University
Phase 4
204
Guangzhou, Shenzhen
2024-11-12
Recruiting
Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL
NCT06742502Primary Mediastinal Diffuse Large B-cell Lymphoma
Sun Yat-sen University
Phase 2
30
Fuzhou, Guangzhou
2024-11-12
Recruiting
Comparison of Endoscopy and Esophagram for the Routine Evaluation of Anastomosis After McKeown Esophagectomy
NCT07043491Esophageal Cancer, Surgery-Complications
Sun Yat-sen University
Observational
2
Guangzhou
2024-11-04
Recruiting
Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
NCT06563999Lung Cancer Stage III, Mutation
Sun Yat-sen University
Phase 2
120
Guangzhou
2024-11-01
Recruiting
Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer
NCT06520683Colorectal Cancer, Microsatellite Instability High
Sun Yat-sen University
Phase 3
180
Guangzhou
2024-11-01
Recruiting
Umbilical Cord Blood NK Cell Therapy for High-Risk Pediatric Soft Tissue Sarcoma: Efficacy and Safety Study
NCT06848582Soft Tissue Sarcoma (STS)
Sun Yat-sen University
Not applicable
40
Guangzhou, Dongguan
2024-11-01
Recruiting
Phase I Study of Umbilical Cord Blood Natural Killer (NK) Cell Therapy for Children With High-risk, R/R Neuroblastoma.
NCT06631391Neuroblastoma
Sun Yat-sen University
Phase 1
30
Guangzhou
2024-11-01
Recruiting
Photoacoustic Tomography in Assessment of Lower Extremity Artery Disease
NCT06579326Lower Extremity, Photoacoustic
Sun Yat-sen University
Observational
200
Guangzhou
2024-11-01
Recruiting
Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients๏ผˆRocket Trial๏ผ‰
NCT06647940Diffuse Large B Cell Lymphoma (DLBCL)
Sun Yat-sen University
Phase 2
39
Guangzhou, Lanzhou, Dongguan, Shantou, Shenzhen, Zhaoqing, Zhuhai
2024-11-01
Recruiting
Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC
NCT06657690Recurrent or Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
56
Zhuhai
2024-11-01
Active, closed
Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
NCT06647732Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
Sun Yat-sen University
Phase 2
42
Guangzhou
2024-10-30
Recruiting
Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study
NCT06848569Classical Hodgkin Lymphoma
Sun Yat-sen University
Phase 2
73
Guangzhou
2024-10-23
Recruiting
Arsenous Acid for Refractory Triple-Negative Breast Cancer
NCT06678048Breast Cancer
Sun Yat-sen University
Phase 2
12
Guangzhou
2024-10-23
Recruiting
Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell Lymphoma
NCT06583083Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
Sun Yat-sen University
Phase 2
84
Guangzhou
2024-10-22
Active, closed
TPC Combined With Cadonilimab VS. TPC Alone in Anti-PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT06664983Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 3
84
Guangzhou
2024-10-21
By invitation
Effect of Intrathecal Morphine on Quality of Recovery After Laparoscopic Colorectal Cancer Surgery
NCT06636864Laparoscopic Colorectal Cancer Surgery
Sun Yat-sen University
Not applicable
252
Guangzhou
2024-10-15
Recruiting
Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma
NCT06644430Advanced Hepatocellular Carcinoma, Lung Cancer, Oligometastasis, Ablation
Sun Yat-sen University
Observational
470
Beijing
2024-10-04
Recruiting
TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT
NCT06622031Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Systemic Therapy
Sun Yat-sen University
Not applicable
42
Beijing
2024-10-01
Recruiting
Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
NCT06609876Hepatocellular Carcinoma, Microwave Ablation, Donafenib, Recurrent Tumor
Sun Yat-sen University
Not applicable
108
Beijing
2024-10-01
Recruiting
The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma
NCT06609850Recurrent Hepatocellular Carcinoma, Lenvatinib, Local Therapy, Ablation
Sun Yat-sen University
Not applicable
116
Beijing
2024-10-01
Recruiting
dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma
NCT06609863Advanced Hepatocellular Carcinoma, Atezolizumab, Bevacizumab, Chemotherapy
Sun Yat-sen University
Not applicable
27
Beijing
2024-10-01
Recruiting
HAIC Compared With TACE in Huge Hepatocellular Carcinoma
NCT06641713Hepatocellular Carcinoma, Hepatic Chemotherapy, Liver Cancer
Sun Yat-sen University
Observational
664
Beijing
2024-10-01
Recruiting
Early Transjugular Intrahepatic Portosystemic Shunt for Advanced Hepatocellular Carcinoma
NCT06624098Advanced Hepatocellular Carcinoma, Variceal Bleeding
Sun Yat-sen University
Not applicable
22
Beijing
2024-10-01
Recruiting
Reduction of Postoperative Radiotherapy in Head and Neck Squamous Cell Carcinoma
NCT06630780Head and Neck Squamous Cell Carcinoma (HNSCC)
Sun Yat-sen University
Not applicable
50
Guangzhou
2024-09-26
Recruiting
2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma
NCT06492460Squamous Cell Carcinoma of Head and Neck
Sun Yat-sen University
Phase 3
422
Guangzhou, Guilin, Changsha, Nanjing
2024-09-20
Recruiting
Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)
NCT06726421Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic, Renal Cell Carcinoma Metastatic
Sun Yat-sen University
Phase 3
252
Fuzhou, Guangzhou, Wuhan, Changchun, Chengdu, Wenzhou, Beijing, Shanghai
2024-09-18
By invitation
Hematoporphyrin Photodynamic Therapy for Esophageal Cancer
NCT06437288Esophageal Cancer, Photodynamic Therapy
Sun Yat-sen University
Phase 4
198
Guangzhou
2024-09-18
Recruiting
Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma
NCT07648069Soft Tissue Sarcoma (STS), Osteosarcoma
Sun Yat-sen University
Phase 1
16
Guangzhou
2024-09-03
Recruiting
Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC
NCT06467799Hepatocellular Carcinoma, Beyond Milan Criteria
Sun Yat-sen University
Phase 2
39
Guangzhou
2024-09-01
Recruiting
Modified Orbital Decompression in the Treatment of Moderate-to-severe Grave's Ophthalmopathy
NCT06588764Graves Ophthalmopathy, Surgery
Sun Yat-sen University
Not applicable
50
Guangzhou
2024-09
Recruiting
Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma
NCT06611150Nasopharyngeal Carcinoma (NPC)
Sun Yat-sen University
Phase 1
24
Guangzhou
2024-08-02
Recruiting
Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma
NCT06550921Advanced Hepatocellular Carcinoma, Oligometastasis, Ablation, Anti-PD1 Antibody
Sun Yat-sen University
Not applicable
60
Beijing
2024-08-01
Recruiting
Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI
NCT06545747Non-small Cell Lung Cancer
Sun Yat-sen University
Phase 3
490
Guangzhou
2024-08-01
Recruiting
Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)
NCT06517511Diffuse Large B Cell Lymphoma
Sun Yat-sen University
Phase 2
42
Guangzhou, Shanghai
2024-08-01
Recruiting
Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.
NCT06675214Nasopharyngeal Carcinoma, De-escalation Therapy
Sun Yat-sen University
Phase 3
586
Zhuhai
2024-07-30
Recruiting
Efficacy and Safety of Organoid-Based Drug Sensitivity Screening to Guide the Treatment of mCRPC Patients Progressed After First-line Treatment
NCT06529549Metastatic Castration-resistant Prostate Cancer
Sun Yat-sen University
Observational
30
Guangzhou
2024-07-24
Active, closed
Neoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular Carcinoma
NCT06524466Resectable Hepatocellular Carcinoma, Macrovascular Invasion, CNLC IIIA Stage
Sun Yat-sen University
Phase 2
35
Guangzhou
2024-07-23
Recruiting
Adebrelimab and Chemoradiotherapy in High-risk LANPC
NCT06349889Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Sun Yat-sen University
Phase 2
50
Xiamen, Guangzhou, Chengdu
2024-07-23
Recruiting
Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study
NCT06547203Colorectal Cancer Metastatic
Sun Yat-sen University
Phase 2
34
Guangzhou
2024-07-18
Recruiting
Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations
NCT06517953Non-small Cell Lung Cancer Metastatic, EGFR G719X, EGFR L861Q, EGFR S768I
Sun Yat-sen University
Phase 2
23
Guangzhou
2024-07-17
Recruiting
Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC
NCT06197776Multi-omics Technique, Nasopharyngeal Carcinoma, Recurrent and Metastatic Nasopharyngeal Carcinoma, Efficacy of Chemoradiotherapy and Immunotherapy
Sun Yat-sen University
Observational
50
Guangzhou
2024-07-15
Recruiting
SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma
NCT06323239Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
148
Guangzhou
2024-07-15
Recruiting
GOS and the Management of Hyperuricemia
NCT06630377Subjects With Hyperuricemia
Sun Yat-sen University
Not applicable
70
Guangzhou
2024-07-15
Recruiting
GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
NCT06455410Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
216
Foshan, Guangzhou, Liuzhou, Nanning, Shantou, Shenzhen, Zhangjiang
2024-06-18
Recruiting
Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen
NCT06456892Rhabdomyosarcoma, Pediatric Cancer
Sun Yat-sen University
Phase 1/2
82
Guangzhou
2024-06-06
Recruiting
TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer
NCT06415318Penile Cancer
Sun Yat-sen University
Phase 2
25
Guangzhou
2024-05-31
Recruiting
Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma
NCT06445088Nasopharyngeal Carcinoma
Sun Yat-sen University
Observational
908
Fuzhou, Guangzhou, Zhongshan, Nanning, Wuzhou
2024-05-29
Recruiting
Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer
NCT06441565Colorectal Cancer
Sun Yat-sen University
Phase 2/3
84
Guangzhou
2024-05-24
Recruiting
A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients
NCT06569485DLBCL
Sun Yat-sen University
Phase 2
38
Guangzhou
2024-05-23
Recruiting
Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary Oligometastases
NCT06542159Adaptive Radiotherapy, Stereotactic Body Radiotherapy, Non-small Cell Lung Cancer, Lung Oligometastases
Sun Yat-sen University
Phase 2
130
Guangzhou
2024-05-22
Recruiting
bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC
NCT06061276Liver Diseases, Hepatocellular Carcinoma, Immunotherapy, Camrelizumab
Sun Yat-sen University
Not applicable
40
Guanzhou
2024-05-20
Recruiting
Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma
NCT06516133Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
494
Guangzhou
2024-05-17
Recruiting
Prebiotics and the Management of Hyperuricemia
NCT06420401Subjects With Hyperuricemia
Sun Yat-sen University
Not applicable
160
Guangzhou
2024-05-15
Recruiting
BAI-BACE for Advanced Lung Squamous Cell Carcinoma
NCT06377735Squamous Cell Carcinoma
Sun Yat-sen University
Not applicable
85
Beijing
2024-05-01
Not yet open
KSD-101 Therapy for Standard Treatment Failed EBV-associated NPC: an Exploratory Clinical Trial
NCT06370026Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase EARLY_PHASE1
12
Guangzhou
2024-05-01
Recruiting
A Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on MTB
NCT06781151Ovarian Cancer Recurrent, Endometrial Cancer Recurrent, Cervical Cancer Recurrent
Sun Yat-sen University
Observational
200
Guangzhou, Shenzhen
2024-04-24
Recruiting
Individualized Elective Neck Irradiation in NPC Patients
NCT06241612Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
470
Guangzhou
2024-04-16
Recruiting
Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)
NCT06313190Hepatocellular Carcinoma
Sun Yat-sen University
Phase 2
140
Guangzhou
2024-04-05
Recruiting
Factors Associated With Posttransplant Cardiac Outcomes
NCT06290154Cardiovascular Diseases, Liver Transplantation
Sun Yat-sen University
Observational
200
Guangzhou
2024-04-01
Recruiting
Endoscopic Surgery vs. Intensity Modulated Radiotherapy for Stage I Nasopharyngeal Carcinoma.
NCT06533267Nasopharyngeal Carcinoma, Intensity Modulated Radiotherapy, Surgery
Sun Yat-sen University
Not applicable
442
Zhuhai
2024-03-25
Recruiting
TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma
NCT06301165Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
162
Guangzhou, Dongguan, Foshan, Shenzhen, Wuhan
2024-03-19
Recruiting
De-escalated Radiotherapy for Primary Tumor After Neoadjuvant Therapy With Toripalimab Plus Chemotherapy for Nasopharyngeal Carcinoma
NCT06313450Nasopharyngeal Carcinoma, Radiotherapy; Complications, IMMUNOTHERAPY
Sun Yat-sen University
Not applicable
112
Guangzhou
2024-03-04
Active, closed
Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006)
NCT06143748Esophagus Cancer
Sun Yat-sen University
Phase 2
46
Guangzhou
2024-03-02
Not yet open
Myeloprotection With Trilaciclib in Pan-cancer Population
NCT06297811Non-Small Cell Lung Cancer, Breast Cancer, Endometrial Cancer, Cervical Cancer
Sun Yat-sen University
Phase 2
132
Guangzhou
2024-03-01
Recruiting
Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)
NCT06187597Locally Advanced Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2
140
Guangzhou
2024-03-01
Recruiting
Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis
NCT06582940MRI-guided Adaptive Radiotherapy, Non-small Cell Lung Cancer, Brain Metastasis
Sun Yat-sen University
Phase 2
168
Guangzhou
2024-03-01
Not yet open
Enhanced External Counter Pulsation on Afterload Mismatch Rate in Post-TEER (PAMPER)
NCT06227286Mitral Regurgitation
Sun Yat-sen University
Not applicable
176
Guangzhou, Jieyang, Shantou, Zhongshan
2024-03-01
Recruiting
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
NCT06239727Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
593
Fuzhou, Xiamen, Dongguan, Foshan, Guangzhou, Shantou, Zhanjiang, Nanning
2024-03-01
Recruiting
Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases
NCT06265350Hepatocellular Carcinoma, Liver Cancer Stage IV, Pulmonary Metastases, Cadonilimab
Sun Yat-sen University
Not applicable
80
Guanzhou
2024-02-02
Recruiting
Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study
NCT07583511Small-cell Lung Cancer
Sun Yat-sen University
Phase 2
90
Guangzhou
2024-02-01
Recruiting
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
NCT06280495Colorectal Cancer, Liver Metastases
Sun Yat-sen University
Phase 2/3
156
Guangzhou
2024-02-01
Not yet open
Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations
NCT06054191NSCLC, BRAF V600 Mutation, MET Exon 14 Mutation
Sun Yat-sen University
Phase 2
40
Guangzhou
2024-02-01
Recruiting
Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)
NCT06733051Natural Killer T-cell Lymphoma
Sun Yat-sen University
Phase 2
47
Beijing, Guangzhou
2024-01-27
Recruiting
Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer
NCT06268652Breast Cancer, Refractory Breast Carcinoma
Sun Yat-sen University
Phase 3
302
Guangzhou
2024-01-15
Recruiting
Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM
NCT06208371Colorectal Neoplasms Malignant
Sun Yat-sen University
Phase 3
117
Guangzhou
2024-01-15
Recruiting
IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
NCT05941741Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy, Chemotherapy
Sun Yat-sen University
Phase 3
380
Guangzhou, Nanning, Nanchang
2024-01-10
Recruiting
Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy
NCT05965531Rectal Cancer
Sun Yat-sen University
Phase 2
65
Guangzhou
2024-01-01
Recruiting
The Cold Ischemia Robot-assisted Partial Nephrectomy
NCT07326280Renal Cell Carcinoma, Renal Function Abnormal
Sun Yat-sen University
Not applicable
310
Guangzhou
2024-01-01
Active, closed
Regulation of Blood-Brain Barrier Permeability by APOE Gene Polymorphism and Its Impact on Cognitive Function Post-Radiotherapy in Nasopharyngeal Carcinoma: An MRI Study
NCT06881225Nasopharyngeal Carcinoma
Sun Yat-sen University
Observational
300
Guangzhou
2024-01-01
Rows per page Showing 201–300 of 490
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china?page=3

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 490 of those studies that match the filters currently applied.

How many clinical trials are recruiting in China?

305 of the 490 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 101 have not yet opened recruitment, 76 are active but closed to new participants, and 8 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Browse trials by condition

Nasopharyngeal Carcinoma (56) Hepatocellular Carcinoma (23) Nasopharyngeal Cancinoma (NPC) (18) Colorectal Cancer (14) Breast Cancer (11) Rectal Cancer (9) Chemotherapy (9) Nasopharyngeal Carcinoma (NPC) (9) Radiotherapy (8) Surgery (7) Non-small Cell Lung Cancer (7) Colorectal Cancer Metastatic (6) Immunotherapy (6) Advanced Hepatocellular Carcinoma (6) Neoadjuvant Therapy (6)

Browse trials by site location

Guangzhou (451) Beijing (25) Shenzhen (23) Zhongshan (17) Nanning (17) Fuzhou (16) Foshan (15) Dongguan (14) Shantou (13) Zhanjiang (12) Nanchang (12) Changsha (12) Wuhan (12) Zhuhai (11) Chengdu (10)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.